Jens Holstein Appointed to Veracyte BOD and James Erlinger as Executive Vice President, General Counsel and Secretary

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Irrimax Receives FDA Clearance for Irrisept

"This new clearance from the FDA further solidifies Irrisept as the market leader in wound irrigation," said Mark Alvarez, CEO of Irrimax.

Veracyte, Inc. today announced the addition of Jens Holstein to the company’s board of directors and the appointment of Jim Erlinger as executive vice president, general counsel and secretary.

“We are thrilled to welcome these two highly accomplished executives to Veracyte,” said Bonnie Anderson, Veracyte’s chairman and chief executive officer. “Jens Holstein and Jim Erlinger each bring extensive life science industry experience and global-market expertise to the company as we prepare to expand our global footprint in 2021. Ultimately, both executives will be invaluable in helping us achieve our vision of delivering our advanced genomic diagnostics tests to physicians and their patients throughout the world on our own distributed instrument platform.”

Mr. Holstein has 25 years of experience in a variety of financial and general management positions at life science and healthcare companies. In 2011, he was appointed chief financial officer of MorphoSys, a clinical-stage biopharmaceutical company based in Munich, Germany. Before joining MorphoSys, Mr. Holstein worked at pharmaceutical company Fresenius Kabi AG, a subsidiary of Fresenius SE, as regional chief financial officer for the Europe/Middle East Region and as managing director of Fresenius Kabi Deutschland GmbH. Prior to that, Mr. Holstein held multiple other leadership positions within the Fresenius SE Group, including managing director of Fresenius ProServe GmbH, chief financial officer and labor director at Wittgensteiner Kliniken AG, general manager of hospitalia care GmbH, commercial manager of the Projects and Service business unit of Fresenius, and commercial manager of hospitalia international GmbH.

Mr. Erlinger is a seasoned attorney and business executive with 35 years of experience in the life sciences, pharmaceutical, drug development and healthcare industries. Mr. Erlinger previously served as executive vice president, general counsel and secretary of IQVIA (formerly Quintiles), a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. At IQVIA, Mr. Erlinger was a member of the Executive Committee and responsible for global legal operations, ethics and compliance, enterprise risk management and quality assurance. Mr. Erlinger spent the balance of his career as a partner of the international law firm of Bryan Cave Leighton Paisner.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles

Join our list

Subscribe to our mailing list and receive an end-of-week recap news and updates delivered right to your email inbox.